Core Insights - Roche plans to invest $50 billion in the U.S. market over the next five years, following Novartis's $23 billion investment, as part of a response to the "America First" tariff policy [1] - This investment is expected to create over 12,000 direct jobs, including 6,500 in infrastructure and 1,000 from new factory construction and existing capacity expansion [1] - Roche aims to transition its U.S. subsidiary from a net importer to a net exporter of pharmaceuticals, enhancing the competitiveness of the domestic pharmaceutical industry [2] Investment Details - The investment will focus on building research and production facilities in Indiana, Pennsylvania, Massachusetts, and California, covering cutting-edge fields such as biopharmaceuticals and gene therapy [1] - The CEO of Roche emphasized that this investment is a commitment to the U.S. market and aims to ensure that the U.S. remains a leader in global biopharmaceutical innovation [1] Strategic Implications - The concentrated investment by multinational pharmaceutical companies indicates the ongoing strategic value of the U.S. market in the global biopharmaceutical landscape [2] - By establishing new R&D bases and smart factories, Roche aims to mitigate the cost impacts of tariff policies on its supply chain [2]